Targets › SLC6A19
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2026.
Transporter that mediates resorption of neutral amino acids across the apical membrane of renal and intestinal epithelial cells. This uptake is sodium-dependent and chloride-independent. (UniProt, Q695T7)
Open in Phaseline: the race on SLC6A19, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | GenSci144 tablets SLC6A19 transporter small molecule inhibitor | SLC6A19 | Phase 1 | Phenylketonuria | Dec 2026 |
Phenylketonuria (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.